Capital One starts Carisma Therapeutics at Overweight, sees 134% upside

Capital One analyst Naureen Quibria initiated coverage of Carisma Therapeutics with an Overweight rating and $10 price target, $134% above current levels. Carisma is a clinical-stage company that is advancing its CAR-macrophage platform for solid tumors, the analyst tells investors in a research note. The firm says the company is a pure play in myeloid cell therapy. It views Carisma as a “truly differentiated” cell therapy company with a core technology and platform geared toward upgrading the macrophage, an area where CAR-T therapy has not yet found any success.